Cardiac Implantable Electronic Devices in Adults with Tetralogy of Fallot.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
15 06 2019
Historique:
received: 06 01 2019
revised: 01 03 2019
accepted: 05 03 2019
pubmed: 10 4 2019
medline: 31 1 2020
entrez: 10 4 2019
Statut: ppublish

Résumé

Patient with repaired tetralogy of Fallot (TOF) sometimes require cardiac implantable electronic devices (CIED) for tachy/bradyarrhythmias. There are no population-based studies of CIED-related outcomes in the adult TOF population. We reviewed the Nationwide/National Inpatient Sample to determine trends in CIED-related admissions in adults with TOF repair. This is a retrospective review of the Nationwide/National Inpatient Sample database from January 1, 2000 to December 31, 2014. There were 18,353 admissions in adults with TOF diagnosis, and of these, CIED were implanted in 792 (4.3%) admissions (CIED-related admissions). Of these 792 CIED-related admissions, pacemakers were implanted in 242 (30.7%) yielding an incidence of 1.3% and implantable cardioverter-defibrillators were implanted in 550 (69.4%) yielding an incidence of 3.0%. In-hospital mortality occurred in 14 (1.8%) of the CIED-related admissions. The mean hospital length of stay was 7.7 ± 1.3 days and inflation-adjusted hospitalization cost was $141,860 ± $127,516. In 5-year intervals (2000 to 2004, 2005 to 2009, and 2010 to 2014), there was a temporal increase in the incidence of CIED-related admissions (3.7% vs 4.4% vs 4.9%, p = 0.006). There was a similar trend in the age at the time of implantation (37.7 ± 14.2 vs 38.2 ± 13.1 vs 39.0 ± 14.5 years, p < 0.001) and Charlson Comorbidity Index (1.1 ± 1.4 vs 1.4 ± 1.8 vs 1.3 ± 1.7, p < 0.001). In conclusion, the incidence of CIED-related admissions was 4.3% and increased over time. Further studies are required to determine if the observed temporal increase in incidence of CIED implantations (particularly implantable cardioverter-defibrillators) is associated with a concomitant increase in incidence of aborted sudden cardiac death.

Identifiants

pubmed: 30961908
pii: S0002-9149(19)30307-8
doi: 10.1016/j.amjcard.2019.03.010
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1999-2001

Subventions

Organisme : NHLBI NIH HHS
ID : K23 HL141448
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Alexander C Egbe (AC)

Department of Cardiovascular Medicine, Mayo Clinic Rochester, Minnesota. Electronic address: egbe.alexander@mayo.edu.

Saraschandra Vallabhajosyula (S)

Department of Cardiovascular Medicine, Mayo Clinic Rochester, Minnesota.

Emmanuel Akintoye (E)

Division of Cardiovascular Medicine, University of Iowa Hospitals and Clinic, Iowa.

Abhishek Deshmukh (A)

Department of Cardiovascular Medicine, Mayo Clinic Rochester, Minnesota.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH